Ia Aperila 2019, na ulufale ai HopeMed i se maliega laisene faʻapitoa i le lalolagi atoa ma Bayer AG i luga o le atinaʻeina ma le faʻatauina o se tagata monoclonal antibody e faʻatatau i le PRL receptor mo le togafitia o le gau o le lauulu tane ma le fafine, endometriosis, ma isi faʻamaʻi faʻamaʻi faʻatasi ma le dysregulated prolactin. (PRL) faailoilo. O lenei antibody ua faʻaalia uiga sili ona lelei i faʻataʻitaʻiga manu e aofia ai faʻataʻitaʻiga NHP ma suʻesuʻega saogalemu o tagata. O ana togafitiga mo faʻailoga autu e lua, endometriosis ma androgenetic alopecia, ua uma ona faʻamaonia e le US FDA mo faʻataʻitaʻiga ile Vaega II. Ole vaega II ole su'esu'ega ile falema'i ole HMI-115 ile endometriosis ua mae'a amataina le lesitalaina o tagata ma'i ile US ile fa'ai'uga o le 2021. O lona Vaega II fa'ata'ita'iga fa'ata'ita'iga mo le togafitiga o le androgenetic alopecia o se nofoaga tutotonu fa'avaomalo, fa'afuase'i, fa'alua tauaso, placebo- suʻesuʻega faʻatonutonu, lea ua fuafua e faia i le Iunaite Setete, Ausetalia ma isi atunuu.

Dr. Henri Doods, le Pule Sili o HopeMed, fai mai “Ou te matua mitamita lava ona ua faamaonia foi e le FDA la tatou IND lona lua lea o se tulaga taua tele mo la tatou kamupani talavou. O se laasaga taua i la tatou misiona e aumai muamua-i-Class ma tulaga ese'ese oloa i gasegase. O le endometriosis ma le alopecia o fa'ailoga ia o lo'o fa'atalitali ai ma'i mo ni togafitiga fou e fa'aleleia atili ai le lelei ma le saogalemu. O le manuia o le mauaina o faʻatagaga IND e lua i se taimi puʻupuʻu o se faʻamalosiaga mo le 'au atoa. Matou te matua tuuto atu e faʻamalosia atili ma faʻalauteleina a matou galuega suʻesuʻe ma faʻataʻitaʻiga e aumai ai ni togafitiga fou fou i gasegase i le lalolagi atoa.

OA MEA E AVEA MAI LENEI TUSI:

Its Phase II clinical trial for the treatment of androgenetic alopecia is an international multi-center, randomized, double-blind, placebo-controlled study, which is planned to be carried out in the United States, Australia and other countries.
In April 2019, HopeMed entered a world-wide exclusive license agreement with Bayer AG on the development and commercialization of a human monoclonal antibody targeting the PRL receptor for the treatment of male and female pattern hair loss, endometriosis, and other chronic diseases with dysregulated prolactin (PRL) signaling.
The success of having two IND approvals in such a short period of time is an encouragement for the whole team.